Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Initial interest in homologous recombination genes was focused on pathologic mutations associated with risk of inherited breast, prostate, pancreatic, and/or gynecological malignancies. HRD has recently emerged as a biomarker to predict sensitivity to PARP inhibitors, and the identification of these alterations has become important, accordingly.

Our panel will discuss several such clinical cases in detail and recommend a course of treatment based on the genomic profiles of the patients.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.